Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke ...

Milvexian is in three late-stage studies in AF, stroke, and acute coronary syndromes (ACS), while abelacimab is in the phase 3 LILAC-TIMI 76 in patients with AF deemed unsuitable for current OAC ...

Milvexian is in three late-stage studies in AF, stroke, and acute coronary syndromes (ACS) in the LIBERXIA programme, while abelacimab is in the phase 3 LILAC-TIMI 76 in patients with AF deemed ...

John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...

The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology. These topics and more were explored at an Institute for Value-Based Care ® event cohosted by AJMC and ...

Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science ...